Trial
NCT02260635
A Study of Evacetrapib (LY2484595) in Japanese Participants With Primary Hypercholesterolemia
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Eli Lilly and Company
Collaborators
—
Condition
Hypercholesterolemia
Intervention
Evacetrapib
Why stopped
Study termination due to insufficient efficacy.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-10-09